Potential Resource Utilization Benefits of Delaying the Progression of Mild Cognitive Impairment (P6.188)

Objective: To describe differences between mild cognitive impairment (MCI) and mild Alzheimer’s disease dementia (AD-D) on healthcare resource utilization Background: Several pipeline drugs are now being tested in MCI patients to see whether they can delay the progression to mild AD-D. Design/Methods: Adelphi Dementia Disease Specific Programme data in 2016 were collected by clinicians in 6 countries (United States, United Kingdom, France, Germany, Italy, Spain). Included patients were age 50 or older with early cognitive impairment or Alzheimer’s disease. Physicians reported healthcare resource utilization (HRU) data. Cross-sectional data were analyzed using descriptive statistics. Values after means are standard deviations. Results: Data were reported for a population of 3587 patients (1479 MCI, 2108 mild). From MCI to mild AD-D, the mean per patient number of hospitalizations in the past 12 months increased by 100% (0.1 (0.5) to 0.2 (0.6)). The length of stay of the most recent hospitalization increased 79.7% (0.7 (3.5) to 1.2 (9.0)). Outpatient hospitalizations were unchanged. Caregiver presence for the patients’ daily needs increased from 42.7 to 80.1% with most of the increase in non-professional care (35.5 to 61.3%), a tripling in combination professional/non-professional care (3.8 to 12.5%), and an almost doubling in professional care (3.4 to 6.3%). Use of donepezil (16.8 to 43.6%), galantamine (2.5 to 5.9%), oral rivastigmine (1.5 to 4.8%), rivastigmine patch (2.5 to 12.0%), and memantine (4.5 to 12.8%) increased. Use of antipsychotics (1.8 to 3.0%), antidepressants (8.6 to 10.7%), benzodiazepines (3.7 to 3.9%), and sleep drugs (2.2 to 3.3%) increased slightly. Conclusions: This study suggests that there are substantial benefits to delaying patient progression from MCI to mild AD-D in needs for a caregiver and use of Alzheimer’s disease medications. Hospitalizations while low, doubled in frequency and almost doubled in duration. Study Supported by: Eisai Inc. Disclosure: Dr. Tsong has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai Inc. Dr. Tsong has received research support from Eisai Inc. Dr. Jones has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with employee of Adelphi Real World and paid consultants for Biogen. Dr. Pike has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employees of Adelphi Real World and paid consultants for Biogen. Dr. Bluff has nothing to disclose.